Morpheus-panBC
Phase 1/2 Recruiting
792 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Phase 1/2 Recruiting
285 enrolled
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Phase 3 Recruiting
1,050 enrolled
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase 3 Recruiting
920 enrolled
MiRaDoR
Phase 2 Recruiting
976 enrolled
CAROLEEN
Recruiting
3,250 enrolled
FourLight-3
Phase 3 Recruiting
1,020 enrolled
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase 2 Recruiting
60 enrolled
CYCAD-1
Phase 1/2 Recruiting
564 enrolled
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Phase 1 Recruiting
28 enrolled
ELECTRA
Phase 1/2 Recruiting
73 enrolled
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Phase 2 Recruiting
28 enrolled
ELAINEIII
Phase 3 Recruiting
500 enrolled
ETHAN - ET for Male BC
Phase 2 Recruiting
60 enrolled
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Phase 1/2 Recruiting
196 enrolled
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
Phase 2 Recruiting
15 enrolled
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
430 enrolled
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Phase 1 Recruiting
15 enrolled
VS-6766+Abema+Fulv in Met HR+/HER- BC
Phase 1/2 Recruiting
63 enrolled
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Phase 2 Recruiting
174 enrolled
AURA
Phase 3 Recruiting
290 enrolled
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Phase 2 Recruiting
43 enrolled
INX-315-01
Phase 1/2 Recruiting
150 enrolled
ABBICAR
Phase 2 Recruiting
53 enrolled
ROYAL
Recruiting
100 enrolled
CAMBRIA-2
Phase 3 Recruiting
5,500 enrolled
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
Phase 2 Recruiting
60 enrolled
MINERVA
Phase 4 Recruiting
300 enrolled
ABBY
Phase 2 Recruiting
66 enrolled
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Phase 1/2 Recruiting
42 enrolled
Neo-AGILE
Phase 2 Recruiting
51 enrolled
PALMARES-2
Recruiting
3,500 enrolled
Rainbow
Phase 3 Recruiting
1,900 enrolled
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3 Recruiting
766 enrolled
ORACLE-RIPA
Phase 2 Recruiting
60 enrolled